MedWatch

Novo Nordisk upgrades full-year guidance

Following a strong Q1 sales performance, Danish pharmaceutical giant Novo Nordisk has adjusted its 2022 outlook upward. (Updated)

Photo: Novo Nordisk / PR

Novo Nordisk has released its Q1 financial report, in which the company announces its new sales growth outlook for 2022 of 10–14 percent in constant exchange rates, up from earlier 6–10 percent, the company reports in a Friday press release.

Moreover, Novo is adjusting its operating growth guidance to 9–13 percent versus the former estimate of 4–8 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs